Hypoglycemia is a risk factor for inpatient mortality among patients in intensive care [6] [7] [8] [9] [10] and in those admitted to the general ward, 11 and it increases the risk of prolonged hospitalization. 12 Furthermore, undetected or untreated hypoglycemic events may lead to neurological damage, cognitive decline, seizures, and coma. 13, 14 Continuous glucose monitoring (CGM), which provides information on changes in interstitial glucose levels, including the direction and rate of change, was proposed as the method of choice to minimize the risk of hypoglycemia among hospitalized patients. Measurement of blood glucose levels every 5 to 10 minutes has advantages over the traditional bedside capillary point-of-care (POC) testing, which is performed before meals and at bedtime. 1 Despite these advantages, recent clinical guidelines do not currently recommend the use of CGM because of insufficient data on its accuracy and safety. 15 The aim of the present study was to evaluate the accuracy and safety of CGM in adult type 2 diabetic patients hospitalized in the general ward, and to assess its potential advantages over POC for the detection of symptomatic or asymptomatic hypoglycemic episodes.
Methods

Patients and Insulinization Strategy
The present study was a prospective pilot study that included 38 medical management patients hospitalized in the general ward of the University Hospital San Ignacio in Bogota, Colombia, between March 2011 and February 2012, with a known history of diabetes mellitus (DM) or without a previous diagnosis of DM but with a blood sugar level on admission of 140-400 mg/dl. Patients excluded from the study were as follows: younger than 18 years or older than 80 years, undergoing surgery during the course of hospitalization, those treated with systemic steroids, requirement for enteral or parenteral nutrition, requiring intensive care management during hospital stay, chronic liver disease or cirrhosis, creatinine clearance < 30 cc/min, pregnant, mental conditions limiting an understanding of the study, and patients with diabetic ketoacidosis or hyperosmolar nonketotic state.
Patients enrolled in the study provided blood samples for HbA1c (measured by high performance liquid chromatography), creatinine, glycemia, and capillary blood glucose measurement. Treatment with oral antidiabetic agents and crystalline insulin and NPH (Neutral Protamine Hagedorn) was discontinued, and patients were placed on a basal insulin bolus regimen with glargine and glulisine (Lantus and Apidra, Sanofi-Aventis, Bridgewater, NJ) according to the protocol described in the RABBIT study. 11 Briefly, patients were started on an initial total daily insulin dose (TDD) of 0.3-0.5 U/kg according to the basal glucose levels, age, and creatinine values. One half of the TDD was administered as a basal glargine dose, and the remaining 50% was administered with glulisine in 3 equal doses at mealtimes. In patients with a fasting glucose of 140-180 mg/dl (7.7-10 mmol/l), the basal insulin dose was increased by 10%, whereas in those with a fasting glucose >180 mg/dl (10 mmol/l), it was increased by 20%. The objective of the treatment was to achieve a fasting glucose level of 100-140 mg/dl (5.5-7.7 mmol/l) and preprandial glucose of 140-180 mg/dl (7.7-10 mmol/l).
Continuous Glucose Monitoring and Point-of-Care Capillary Blood Glucose Monitoring
POC glucose monitoring was performed before meals and at 2 h after meals, at bedtime, and at 3 am starting on admission to the hospital. The glucometer used was from Abbott (FreeStyle Precision Pro, Alameda, CA). Capillary blood glucose values were systematically recorded and used to determine the daily insulin dose.
CGM was initiated on the second day of hospitalization with a CGMS iPro-2 (Medtronic, Northridge, CA ) following the insertion of a subcutaneous sensor in the anterior region of the abdomen of each patient, and monitoring was performed for a maximum of 6 days. Calibration of the CGM was done following the iPro-2 producer recommendations, using capillary blood glucose measures in range between 40 and 400 mg/dl, 1 and 3 hours after the insertion of a subcutaneous sensor, and then previous to each meal until the end of the study. At the end of this period, the equipment was removed and data were downloaded using the iPro CareLink software. Patients and hospital personnel were blinded to the results of CGM. Hypoglycemic episodes were defined as a blood glucose level < 70 mg/dl (< 3.8 mmol/l) as detected by conventional capillary blood glucose monitoring regardless of the presence of symptoms. Additional evaluation was done defining hypoglycemia as a glucose level < 60 mg/dl (< 3.3 mmol/l).
Statistical Analysis
Statistical analyses were performed using SPSS v18 (SPSS Inc, Chicago, IL). Descriptive data analysis was performed. The rates of incidence of hypoglycemia were calculated based on the data obtained by CGM and POC, and the incidence rate ratio (IRR) between them was determined. Student's t test was used to compare systems, global, preand postprandial average glucose levels. Values of P < .05 were considered statistically significant.
Results
Characteristics of the Study Participants
The study included 38 patients, of which most were men. Two patients were excluded for missing data on CGM. The average age on admission was 66.1 ± 8.6 years, the duration of diabetes was 14.8 ± 9 years, glucose level on admission was 251 ± 9 mg/dl, BMI was 26.5 ± 4.9 kg/m 2 , and glycosylated hemoglobin was 9.26 ± 2.62% (78 ± 17 mmol/mol). At least 1 comorbidity was detected in 84.2% of patients (Table 1 ). The average number of days under CGM was 4.3 ± 1.0 days.
Glucose Concentration
No significant differences in the average daily glucose levels measured by CGM and POC were observed after the first day of treatment (176.2 ± 33.9 vs 176.6 ± 33.7 mg/dl, P = .828) ( Figure 1 ). Ten patients (26.3%) had at least 1 episode of hypoglycemia defined as glucose level < 70 mg /dl (< 3.8 mmol/l) during follow-up. Overall, 55 episodes of hypoglycemia were detected by CGM (1.45 episodes per patient) compared to 12 episodes detected by POC (0.32 episodes per patient), indicating that CGM was more effective than POC for the detection of hypoglycemia (IRR = 4.58, 95% confidence interval: 2.42-9.40, P < .0001).
Of the total hypoglycemic episodes, 60% occurred between dinner and 6 am. A total of 46 (86.7%) episodes of hypoglycemia were detected exclusively by CGM. Thirteen episodes of hypoglycemia were asymptomatic. CGM was more effective than POC for the detection of symptomatic and asymptomatic hypoglycemia both at daytime and nighttime (P = .0001) ( Table 2 ).
Defining hypoglycemia as glucose level below 60 mg /dl (<3.3 mmol/l), we found 30 episodes detected by CGM compared to 6 episodes detected by POC (IRR = 5, 95% confidence interval: 2.5-14.28, P < .0001). No episodes of hypoglycemia < 40 mg/dl were detected by either of the 2 methods.
Accuracy of Measurements
The numerical accuracy of the measurements obtained by CGM was determined according to the ISO criteria (16) . Measurements were found to be accurate for both, glucose values > 75 mg/dl (4.33 mmol/l), with an absolute difference of means of 12.9%, and for measurements < 75 mg/dl, with only 0.6% of the values showing a difference greater than 15 mg/dl (0.83 mmol/l) compared to POC. Pearson correlation analysis revealed a positive correlation between interstitial glucose values by CGM and corresponding capillary blood glucose (r = .79). In addition, the clinical accuracy was determined using the Clarke error grid, which showed that 91.9% of the data were within the A and B zones ( Figure 2 ).
Discussion
Adequate glycemic control is an important objective in the management of hospitalized type 2 diabetic patients, and a basal bolus insulin regimen is the method of choice to achieve this goal. 15, 16 The primary objective of the present pilot study was to perform a systematic comparison of CGM and POC for the detection of episodes of hypoglycemia, and our results showed that CGM is the superior method. In addition, we evaluated the accuracy of measurements obtained by CGM and POC, both to determine average glucose levels and for the detection of hypoglycemic episodes. The present study is the first evaluation limited to type 2 general medicine diabetic patients, among which the average BMI was found to be in the overweight range (BMI: 26.7), which is lower than that reported in previous studies, in which the majority of patients were obese. Similar to previous reports, 17, 18 our study showed that the average daytime glucose level measurements are comparable between CGM and POC. However, the main difference between the 2 methods was the ability to detect episodes of hypoglycemia. In the present cohort, 55 episodes of hypoglycemia were detected by CGM, of which 86.7% were detected exclusively with this method. The fact that more than 50% of these hypoglycemic episodes occurred between dinner and 6 am indicates that these episodes could not have been detected by POC. This could lead to poor clinical outcomes among these patients, in particular considering that a significant percentage of these hypoglycemia episodes (26.3%) were asymptomatic. The present study also provides important information regarding the accuracy of glucose measurements obtained by CGM. We independently evaluated the accuracy of the results obtained based on glucose values above and below 75 mg/dl (4.33 mmol/l) according to the ISO guidelines. 19 Our results showed that the measurements were accurate in both instances, demonstrating the usefulness of CGM for the detection of both hyper-and hypoglycemia. Similarly, assessment of the clinical accuracy of the results using Clarke's error grid showed that the clinical decisions potentially made on the basis of these results should be accurate in 92% of the cases. Furthermore, the safety of this technology was demonstrated by the fact that no severe symptoms associated with subcutaneous catheter insertion or infectious complications were detected among our patients.
The main limitation of our study was the relatively low number of episodes of hypoglycemia among our patients, which limits the assessment of the accuracy of the results in the glucose range below 75 mg/dl (4.33 mmol/l). Future studies should evaluate this issue in further detail.
CGM could potentially improve our ability to detect episodes of hyper-and hypoglycemia among hospitalized patients over that of POC. However, the use of this technology has generated concern because of its high cost and because data on its accuracy and safety in inpatients are limited; therefore, its use is not currently recommended by international guidelines. 15 The present results provide a basis for further investigation aimed at determining whether real-time CGM, when combined with a predefined and specific therapeutic regimen, can reduce the incidence of hypo-and hyperglycemia episodes in the context of type 2 diabetes patients hospitalized in the general ward, as previously demonstrated in type 1 ambulatory patients, in which CGM was shown to reduce the duration of hypoglycemic episodes, 20 and in critical care patients, in which studies have shown a lower incidence of severe hypoglycemia. 18, 21 However, because this information is not currently available, the recommended method for the monitoring of glucose levels is POC glucose monitoring before meals and at bedtime, as proposed by international guidelines. 
Conclusions
Our preliminary results indicate that the use of CGM in type 2 patients hospitalized in the general ward provides accurate estimation of blood sugar levels and is more effective than POC for the detection of hypoglycemic episodes and asymptomatic hypoglycemia.
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